Full Text (PDF)
Original Article

Role of low hemoglobin level in predicting response to neoadjuvant chemotherapy in breast cancer and its correlation with p53, bcl-2 and VEGF – a prospective clinical study

Chintamani* , Chintamani* J.P. Singh** Rohan Khandelwal*** Megha Tandon**** Usha Agarwal***** Sunita Saxena******

Author Information

Licence:




New Indian Journal of Surgery 1(1):p 13-21, Oct-Dec 2010. | DOI:

How Cite This Article:


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

Neo-adjuvant chemotherapy (NACT) is an integral part of multi-modality approach in the management of locally advanced breast cancer (LABC). It is required both for the local control (to ensure microscopically free margins during surgery) and distant or systemic control [1-6]. Development of resistance to chemotherapeutic agents is a major and evolving problem. Various markers like P-Glycoprotein, tumor suppressor gene p53, apoptotic markers( Bcl-2, Bax) have been studied to predict the response to NACT[1].

Key words: Hemoglobin, breast cancer, neoadjuvant, Chemotherapy.


References

No records found.


About this article


Cite this article


Licence:




Received Accepted Published
N/A N/A N/A

DOI:

Keywords


Article Level Metrics

Last Updated

Saturday 28 February 2026, 14:06:37 (IST)


507

Accesses

0
158
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share